Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1year: a systematic review and meta-analysis
      QxMD      Google Scholar   
Citation:
Lancet Oncol. vol 20 (3) 361-370
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Meta-Analysis
Data Sharing:
Alliance-data-source,-external-user
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
8
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821  
Corr. Author:
 
Authors:
                         
Networks:
NY018, PR028   
Study
Alliance-A151716
Multiple Studies, or Legacy Studies in Alliance Study:
NCCTG-N9831, NSABP B-31
Phases:
N/A, 3
Keywords:
Article